Associated Papers
Pachydermoperiostosis Associated With a Rare SLCO2A1 Mutation: A Case Report and Literature Review.
Mohammad M et al.
Cureus, 2025
Genotype and phenotype characterization of primary hypertrophic osteoarthropathy type 2 and chronic enteropathy associated with SLCO2A1: Report of two cases and literature review.
Kimball TN et al.
American Journal of Medical Genetics. Part A, 2024
Recent advances in studies of SLCO2A1 as a key regulator of the delivery of prostaglandins to their sites of action.
Nakanishi T et al.
Pharmacology & Therapeutics, 2021
The ATP-Releasing Maxi-Cl Channel: Its Identity, Molecular Partners and Physiological/Pathophysiological Implications.
Sabirov RZ et al.
Life (basel, Switzerland), 2021
Roles of Organic Anion Transporting Polypeptide 2A1 (OATP2A1/SLCO2A1) in Regulating the Pathophysiological Actions of Prostaglandins.
Nakanishi T et al.
The Aaps Journal, 2017
Identification of two novel mutations in the SLCO2A1 prostaglandin transporter gene in a Chinese patient with primary hypertrophic osteoarthropathy.
Guo T et al.
Molecular Medicine Reports, 2017
Pachydermoperiostosis Masquerading as Acromegaly.
Karimova MM et al.
Journal of the Endocrine Society, 2017
Identification of the Mutations in the Prostaglandin Transporter Gene, SLCO2A1 and Clinical Characterization in Korean Patients with Pachydermoperiostosis.
Lee S et al.
Journal of Korean Medical Science, 2016
Mutations in the SLCO2A1 gene and primary hypertrophic osteoarthropathy: a clinical and biochemical characterization.
Zhang Z et al.
The Journal of Clinical Endocrinology and Metabolism, 2013
Mutations in the prostaglandin transporter SLCO2A1 cause primary hypertrophic osteoarthropathy with digital clubbing.
Busch J et al.
The Journal of Investigative Dermatology, 2012
Exome sequencing identifies SLCO2A1 mutations as a cause of primary hypertrophic osteoarthropathy.
Zhang Z et al.
American Journal of Human Genetics, 2012
Select a paper to view details